OR4L1

Across TCGA pan-cancer cohorts, OR4L1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR4L1 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR4L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4L1 expression acts as an unfavorable survival marker.

CESC, BRCA, and BLCA are the cancer types where OR4L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.068	0.875	<.001	36	view →
BRCA	DFS	Median	III,IV	0.093	0.880	<.001	22	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
OV	DFS	Median	II,III,IV	0.244	0.542	.008	18	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR4L1–CESC (OS)

Open the CESC breakdown →